# Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile

## TL;DR

This study analyzed the genetic mutations in uterine leiomyosarcoma and found that tumor suppressor genes like TP53 and RB1 are frequently mutated, suggesting new therapeutic strategies.

## Contribution

The study provides a comprehensive mutational profile of uterine leiomyosarcoma using large genomic databases.

## Key findings

- TP53 was the most frequently mutated gene, affecting 61% of patients.
- RB1 mutations often co-occurred with TP53 mutations but were mutually exclusive with CDKN2A/B inactivation.
- PTEN alterations were more common in metastases than in primary tumors.

## Abstract

Uterine Leiomyosarcoma (uLMS) is by far the most common type of uterine sarcoma, characterized by an aggressive clinical course, a heterogeneous genetic profile and a very scarce response to cytotoxic chemotherapy. The genetic make-up of uLMS is an area of active study that could provide essential cues for the development of new therapeutic approaches. A total of 216 patients with uLMS from cBioPortal and AACR-GENIE databases were included in the study. The vast majority of patients (81%) carried at least one mutation in either TP53, RB1, ATRX or PTEN. The most frequently mutated gene was TP53, with 61% of the patients harboring at least one mutation, followed by RB1 at 48%. PTEN alteration was more frequent in metastases than in primary lesions, consistent with a later acquisition during tumor progression. There was a significant trend for TP53 and RB1 mutations to occur together, while both TP53 and RB1 were mutually exclusive with respect to CDKN2A/B inactivation. Overall survival did not show significant correlation with the mutational status, even if RB1 mutation emerged as a favorable prognostic factor in the TP53-mutant subgroup. This comprehensive analysis shows that uLMS is driven almost exclusively by the inactivation of tumor suppressor genes and suggests that future therapeutic strategies should be directed at targeting the main genetic drivers of uLMS oncogenesis.